All In Biotech

Investigational drug · Phase 3

Chiauranib

Also called: CS2164

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

17

Any phase or sponsor naming "Chiauranib"

First trial start

2022

Aug 25, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Chiauranib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Soft Tissue Sarcoma

Approved drugs for the same conditions: Pancreatic cancer · Sarcoma · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Chiauranib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Pancreatic Ductal Adenocarcinoma

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • IBI343Arcotatug TavatecanPhase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma

  • NavlimetostatBMS-986504, MRTX1719Phase 34 trials

    Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors

  • [18F]FAPI-74 PETPhase 33 trials

    SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction

  • SBP-101ivospeminPhase 31 trial

    Panbela Therapeutics, Inc. · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

  • GFH276Phase 25 trials

    Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.